At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- Mix of remote tasks and in-person visits
- Drug or intervention
- Xeomin (drug), Placebo (drug)
- How long the study runs
- Study runs about 26 months (dates as stated)
- About the drug or intervention
- Xeomin — drug: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl) · Placebo — drug: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
- Patient visit burden
- "Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total." (as stated by sponsor)
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 990
- Started
- 2025-08-21
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for episodic migraine
- • Phase3 - 990 participants
- • In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with episodic migraine
Where?
- • Stoke-on-Trent - Royal Stoke University Hospital, Merz Investigational Site #0440048
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Participant age \< 50 years at the time of migraine onset;
- ✓During the last 28 days of the screening period, participant experiencing: ≤ 14 headache days and 6 to 14 migraine...
Who cannot take part
- ✗Diagnosis of chronic migraine;
- ✗Diagnosis of other primary headache types, except tension-type headache, which is permitted;
- ✗Diagnosis of secondary headache types, except medication overuse headache, which is permitted;
- ✗Currently taking \> 1 prescribed drug for the preventive treatment of migraine;
- ✗Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment...
See the full criteria
Where Is This Study? (1 UK site)
Royal Stoke University Hospital, Merz Investigational Site #0440048
Stoke-on-Trent ST4 6QG, United Kingdom
How to Get in Touch
Public Disclosure Manager
Sponsor contactCONTACT